Femina II
Dietary Supplement2 capsules per day until delivery
NCT Number: NCT03864549
Scientific background: Uncontrolled gestational diabetes mellitus (GDM) is associated with severe maternal and neonatal morbidities. Treatment of GDM is multidisciplinary and includes lifestyle changes and medications. However, the efficacy of these treatments is limited due to poor motivation, daily painful blood tests and multiple injections.
Probiotic supplements were shown to modulate the gut microbiome by reducing the adverse metabolic effects associated with pathogenic microbial colonization. Promising effects on glycemic control and insulin resistance in non-pregnant diabetic patients were reported. However, the effect of probiotics on glycemic control in GDM has not been elucidated.
Objectives: To examine the effect of a mixture of probiotic strains given daily on maternal glycemic parameters, and pregnancy outcomes among women with GDM.
Working hypothesis: Oral administration of probiotics will be effective in glucose control of patients with GDM and their neonates without causing significant adverse effects.
Type of research and methods of data collection: A prospective randomized, double blind, placebo controlled trial. Women newly diagnosed with GDM will be recruited and followed in the GDM clinic and Maternal-Fetal Medicine ward (including the research clinic) at Emek Medical Center. They will be divided into a research group, receiving the probiotic formula Femina II and a control group, receiving a placebo (2 capsules/day) until delivery. Glycemic control will be evaluated by daily glucose charts. After 2 weeks of diet and probiotic/placebo treatment and thereafter, pharmacotherapy will be started in case of poor glycemic control according to the daily glucose charts. Blood tests for glycated molecules will be performed. Fetal well-being and growth will be assessed. The primary outcomes are:
1. The rate of women requiring medications for glycemic control 2. Mean value of the mean daily glucose charts after 2 weeks of treatment with the study products.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Assuta-Ashdod medical center, Ashdod, Israel
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 capsules per day until delivery
2 capsules per day until delivery
Time frame: During the length of pregnancy (up to 9 months)
Time frame: 2 weeks
Time frame: During the length of pregnancy (up to 9 months)
Time frame: During the length of pregnancy (up to 9 months)
Time frame: During the length of pregnancy (up to 9 months)
Time frame: During the length of pregnancy (up to 9 months)
Time frame: During the length of pregnancy (up to 9 months)
Time frame: During the length of pregnancy (up to 9 months)
Time frame: At delivery
Time frame: At delivery
Time frame: At delivery
Time frame: At delivery
Time frame: Within a week from delivery
Time frame: Within 1-5 minutes after delivery
Time frame: Within 1-2 days after delivery
Time frame: Within a week from delivery
Time frame: Within a week from delivery
Time frame: Within a week from delivery
Time frame: Within a week from delivery
Time frame: At delivery
Time frame: 1-2 days after delivery
Time frame: At delivery
Time frame: 1-2 days after delivery
Time frame: During the length of pregnancy (up to 9 months)
Time frame: During the length of pregnancy (up to 9 months)
HaEmek Medical Center, Israel
Other
The Effect of Oral Probiotics on Glycemic Control of Women With Gestational Diabetes Mellitus - Randomized, Double Blind, Placebo Controlled Trial, Phase 4
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06431997
Behavior, Behavior, Animal
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05852054
Cardiovascular Diseases, Diabetes Mellitus
Chicago, Illinois, United States
View Trial DetailsNCT01329016
Diabetes Mellitus, Diabetes, Gestational
Indianapolis, Indiana, United States
View Trial DetailsNCT03023293
Allergic Diseases, Behavior
Guangzhou, Guangdong, China
View Trial Details